Okay, here’s a breakdown of the provided text, focusing on the key details about the study and its findings. I’ll organize it for clarity:
Study Overview
* Focus: Evaluating the combination of anlotinib (a tyrosine kinase inhibitor) with chemotherapy (anthracyclines and ifosfamide) for advanced soft tissue sarcoma (STS).
* Patient Population: 52 patients with unresectable, locally advanced, or metastatic high-grade STS. Mean age was 49.1 years.
* Treatment Regimen:
* Anlotinib: 12 mg orally daily for 14 days per cycle.
* Anthracycline: Either 40mg epirubicin (days 1 & 2) or 30mg liposomal doxorubicin (day 1) - IV.
* Ifosfamide: 2g IV on days 1-3.
* Cycles: 4-6 cycles, repeated every 21 days.
* Monitoring period: December 2021 – June 2024.
Key Findings (Compared to Previous Trials)
* Comparison to SAINT Study (Phase 2): The study builds on findings from phase 2 of the SAINT study (NCT03138161), which assessed trabectedin plus ipilimumab and nivolumab.
* SAINT Study Results: The SAINT study showed encouraging safety and efficacy with an Objective Response Rate (ORR) of 24.7% and a Disease Control Rate (DCR) of 82.5%.
* Implication: The findings suggest that combining targeted/immune inhibitors with chemotherapy may improve progression-free survival (PFS) and overall prognosis in advanced STS.
Outcomes Measured
* Objective Response Rate (ORR)
* Disease Control rate (DCR)
* Progression-Free Survival (PFS)
* Overall Survival (OS)
* Treatment-related adverse events.
Links Provided in the Text:
* https://www.ajmc.com/view/first-line-combo-yields-strong-results-in-advanced-sarcoma (Article about the study)
* https://clinicaltrials.gov/study/NCT03138161 (SAINT study information)
Let me know if you’d like me to elaborate on any specific aspect of this information!
